{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:42:03Z","timestamp":1794584523248,"version":"4.9.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) has emerged as a promising therapy for both resectable urothelial carcinoma (UC) patients preparing for radical surgery and unresectable UC patients, whereas the objective response rate of ICB remains unsatisfactory due to various factors. Antibiotic (ATB) use can influence intratumoral bacteria, which may further reduce ICB efficacy. The study aims to evaluate the effects of ATB use on prognosis and response in UC patients undergoing ICB, and explore potential molecular mechanisms of ATBs and intratumoral bacteria impacting UC immune microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Pooled analyses, synthesizing evidence from 3496 UC patients with ICB treatment, were conducted. In addition, single-cell RNA and single-cell microbiome data were analyzed based on eight UC samples and 63\u00a0185 single cells. Bulk RNA sequencing and clinical data from a single-arm, multicenter, atezolizumab-treated, phase 2 trial, IMvigor210, were used for validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      ATB use exhibited worse overall survival (HR=1.46, 95% CI=[1.20\u20131.77],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001 and lower objective response (OR=0.43, 95% CI=[0.27\u20130.68],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001 in UC patients receiving ICB. Single-cell transcriptome and single-cell microbiome analyses identified the presence of intratumoral bacteria was obviously related to elevated antibacterial immune functions; and antibacterial immunity was positively correlated to antitumor immunity in UC immune microenvironment. Intratumoral bacteria could up-regulate\n                      <jats:italic toggle=\"yes\">CD74-MIF\/COPA<\/jats:italic>\n                      signaling of immune cells and activation of\n                      <jats:italic toggle=\"yes\">CD74-MIF\/COPA<\/jats:italic>\n                      mediated the promotion of T cell antitumor function induced by antibacterial immune cells. UC patients with higher\n                      <jats:italic toggle=\"yes\">CD74-MIF\/COPA<\/jats:italic>\n                      signaling carried better overall survival (HR=1.60, 95% CI=[1.19\u20132.15],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.002) in immunotherapy cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      ATB use reduces overall survival and objective response to ICB in UC patients. Antibacterial immune cell functions induced by intracellular bacteria in the UC microenvironment might up-regulate the function of antitumor T immune cells via activating\n                      <jats:italic toggle=\"yes\">CD74-MIF\/COPA<\/jats:italic>\n                      , whereas ATB could inhibit the above process through killing intracellular bacteria and result in poorer clinical benefit of ICB. The use of ATB should be considered carefully during the neoadjuvant immunotherapy period for resectable UC patients preparing for radical surgery and during the immunotherapy period for unresectable UC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000001901","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:03:43Z","timestamp":1720778623000},"page":"972-987","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Antibiotic use attenuates response to immune checkpoint blockade in urothelial carcinoma via inhibiting CD74-MIF\/COPA: revealing cross-talk between anti-bacterial immunity and ant-itumor immunity"],"prefix":"10.1097","volume":"111","author":[{"given":"Yuxuan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"New Engl J Med"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology Guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20260304","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Network Open"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","article-title":"Microbiome and cancer","volume":"39","author":"Cullin","year":"2021","journal-title":"Cancer Cell"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","article-title":"The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1021\/acsnano.2c11305","article-title":"Synergistic target of intratumoral microbiome and tumor by metronidazole\u2013fluorouridine nanoparticles","volume":"17","author":"Gao","year":"2023","journal-title":"Acs Nano"},{"key":"R12-20260304","article-title":"Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses","author":"Wang","year":"2023","journal-title":"Nat Biotechnol"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2021.05.018","article-title":"Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab?","volume":"80","author":"Pederzoli","year":"2021","journal-title":"Eur Urol"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bco2.118","article-title":"Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma","volume":"3","author":"Okuyama","year":"2022","journal-title":"BJUI Compass"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"834.e21","DOI":"10.1016\/j.urolonc.2021.05.033","article-title":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","volume":"39","author":"Ishiyama","year":"2021","journal-title":"Urol Oncol"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"key":"R20-20260304","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol Oncol"},{"issue":"16_suppl","key":"R21-20260304","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/JCO.2022.40.16_suppl.4578","article-title":"Association of antibiotic therapy and treatment efficacy in urothelial cell carcinoma patients receiving immune checkpoint inhibitors","volume":"40","author":"Braun","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"R22-20260304","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JCO.2019.37.7_suppl.435","article-title":"Impact of concurrent medications on outcomes with PD1\/PD-L1 inhibitors for metastatic urothelial carcinoma","volume":"37","author":"Agarwal","year":"2019","journal-title":"J Clin Oncol"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/iju.15151","article-title":"Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab","volume":"30","author":"Tomisaki","year":"2023","journal-title":"Int J Urol"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.3390\/cancers15245780","article-title":"Prognostic factors of platinum-refractory advanced urothelial carcinoma treated with pembrolizumab","volume":"15","author":"Akashi","year":"2023","journal-title":"Cancers"},{"key":"R25-20260304","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/djy088","article-title":"Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration","volume":"110","author":"Sauerbrei","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.ccell.2022.09.009","article-title":"Tumor microbiome links cellular programs and immunity in pancreatic cancer","volume":"40","author":"Ghaddar","year":"2022","journal-title":"Cancer Cell"},{"key":"R29-20260304","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13059-019-1891-0","article-title":"Improved metagenomic analysis with Kraken 2","volume":"20","author":"Wood","year":"2019","journal-title":"Genome Biol"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13059-018-1568-0","article-title":"KrakenUniq: confident and fast metagenomics classification using unique k-mer counts","volume":"19","author":"Breitwieser","year":"2018","journal-title":"Genome Biol"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s43588-023-00507-1","article-title":"Denoising sparse microbial signals from single-cell sequencing of mammalian host tissues","volume":"3","author":"Ghaddar","year":"2023","journal-title":"Nat Comput Sci"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrg3642","article-title":"Sequencing depth and coverage: key considerations in genomic analyses","volume":"15","author":"Sims","year":"2014","journal-title":"Nat Rev Genet"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40168-018-0605-2","article-title":"Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data","volume":"6","author":"Davis","year":"2018","journal-title":"Microbiome"},{"key":"R34-20260304","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2022.02.003","article-title":"Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials","volume":"17","author":"Hopkins","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R35-20260304","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ijms22010042","article-title":"Infections and immunotherapy in lung cancer: a bad relationship?","volume":"22","author":"Belluomini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R36-20260304","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"R37-20260304","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"R38-20260304","doi-asserted-by":"crossref","first-page":"e006643","DOI":"10.1136\/jitc-2022-006643","article-title":"Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R39-20260304","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2326-6066.CIR-21-0326","article-title":"Macrophage-targeted therapy unlocks antitumoral cross-talk between IFN\u03b3-secreting lymphocytes and IL12-producing dendritic cells","volume":"10","author":"Pfirschke","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"R40-20260304","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"R41-20260304","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"R42-20260304","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type\u2013specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"R43-20260304","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.cell.2022.02.027","article-title":"Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer","volume":"185","author":"Fu","year":"2022","journal-title":"Cell"},{"key":"R44-20260304","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-3532-1_1","article-title":"B cell development and maturation","volume":"1254","author":"Wang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R45-20260304","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R46-20260304","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","article-title":"Developmental and functional heterogeneity of monocytes","volume":"49","author":"Guilliams","year":"2018","journal-title":"Immunity"},{"key":"R47-20260304","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"R48-20260304","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-cellbio-092910-154008","article-title":"Mechanisms of T cell development and transformation","volume":"27","author":"Koch","year":"2011","journal-title":"Annu Rev Cell Dev Bi"},{"key":"R49-20260304","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/imr.12266","article-title":"Macrophage defense mechanisms against intracellular bacteria","volume":"264","author":"Weiss","year":"2015","journal-title":"Immunol Rev"},{"key":"R50-20260304","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.micinf.2010.10.015","article-title":"Cell-mediated immunity in human brucellosis","volume":"13","author":"Skendros","year":"2011","journal-title":"Microbes Infect"},{"key":"R51-20260304","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00011-016-0995-1","article-title":"The biological function and significance of CD74 in immune diseases","volume":"66","author":"Su","year":"2017","journal-title":"Inflamm Res"},{"key":"R52-20260304","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/art.20470","article-title":"Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice","volume":"50","author":"Gregory","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R53-20260304","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat Genet"},{"key":"R54-20260304","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41590-019-0323-3","article-title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape","volume":"20","author":"Hubel","year":"2019","journal-title":"Nat Immunol"},{"key":"R55-20260304","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J Exp Med"},{"key":"R56-20260304","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2017.10.001","article-title":"Type I interferon pathway activation in COPA syndrome","volume":"187","author":"Volpi","year":"2018","journal-title":"Clin Immunol"},{"key":"R57-20260304","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41585-019-0171-9","article-title":"MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential","volume":"16","author":"Penticuff","year":"2019","journal-title":"Nat Rev Urol"},{"key":"R58-20260304","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","article-title":"Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts","volume":"161","author":"Bortolomeazzi","year":"2021","journal-title":"Gastroenterology"},{"key":"R59-20260304","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00262-023-03604-2","article-title":"CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1\/CTLA-4 bispecific antibody in patients with solid tumors","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"R60-20260304","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"R61-20260304","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1186\/s12885-019-6267-z","article-title":"The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study","volume":"19","author":"Kim","year":"2019","journal-title":"Bmc Cancer"},{"key":"R62-20260304","doi-asserted-by":"crossref","first-page":"e1507670","DOI":"10.1080\/2162402X.2018.1507670","article-title":"Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors","volume":"7","author":"Ahmed","year":"2018","journal-title":"Oncoimmunology"},{"key":"R63-20260304","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.22.00074","article-title":"Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study","volume":"41","author":"Eng","year":"2023","journal-title":"J Clin Oncol"},{"key":"R64-20260304","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.3390\/molecules26237153","article-title":"Biological effects of quinolones: a family of broad-spectrum antimicrobial agents","volume":"26","author":"Millanao","year":"2021","journal-title":"Molecules"},{"key":"R65-20260304","doi-asserted-by":"crossref","first-page":"104834","DOI":"10.1016\/j.ebiom.2023.104834","article-title":"The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors","volume":"97","author":"Joachim","year":"2023","journal-title":"Ebiomedicine"},{"key":"R66-20260304","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","article-title":"Anticancer effects of the microbiome and its products","volume":"15","author":"Zitvogel","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"R67-20260304","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1038\/s41467-021-25246-7","article-title":"Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"R68-20260304","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/0008-5472.CAN-22-2224","article-title":"Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res"},{"key":"R69-20260304","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1002\/ctm2.1070","article-title":"Single\u2010cell and spatial transcriptomics reveal the fibrosis\u2010related immune landscape of biliary atresia","volume":"12","author":"Ye","year":"2022","journal-title":"Clin Transl Med"},{"key":"R70-20260304","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.3748\/wjg.15.2855","article-title":"CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract","volume":"15","author":"Beswick","year":"2009","journal-title":"World J Gastroentero"},{"key":"R71-20260304","doi-asserted-by":"crossref","first-page":"101251","DOI":"10.1016\/j.xcrm.2023.101251","article-title":"Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Rep Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:03:42Z","timestamp":1772625822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000001901","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"2023-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}